DK147362C - Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf - Google Patents

Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf

Info

Publication number
DK147362C
DK147362C DK051379A DK51379A DK147362C DK 147362 C DK147362 C DK 147362C DK 051379 A DK051379 A DK 051379A DK 51379 A DK51379 A DK 51379A DK 147362 C DK147362 C DK 147362C
Authority
DK
Denmark
Prior art keywords
ergolen
analogue
preparation
acid addition
addition salts
Prior art date
Application number
DK051379A
Other languages
Danish (da)
English (en)
Other versions
DK147362B (da
DK51379A (da
Inventor
Edmund Carl Kornfeld
Nicholas James Bach
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK51379A publication Critical patent/DK51379A/da
Publication of DK147362B publication Critical patent/DK147362B/da
Application granted granted Critical
Publication of DK147362C publication Critical patent/DK147362C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK051379A 1978-02-08 1979-02-07 Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf DK147362C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/875,978 US4166182A (en) 1978-02-08 1978-02-08 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US87597878 1978-02-08

Publications (3)

Publication Number Publication Date
DK51379A DK51379A (da) 1979-09-18
DK147362B DK147362B (da) 1984-07-02
DK147362C true DK147362C (da) 1988-06-27

Family

ID=25366703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK051379A DK147362C (da) 1978-02-08 1979-02-07 Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf

Country Status (36)

Country Link
US (1) US4166182A (cs)
EP (1) EP0003667B1 (cs)
JP (1) JPS54115400A (cs)
AR (1) AR228341A1 (cs)
AT (1) AT371817B (cs)
AU (1) AU523172B2 (cs)
BE (1) BE873883A (cs)
BG (1) BG30474A3 (cs)
CA (1) CA1114368A (cs)
CH (1) CH639088A5 (cs)
CS (1) CS203951B2 (cs)
DD (1) DD141928A5 (cs)
DE (2) DE2963320D1 (cs)
DK (1) DK147362C (cs)
EG (1) EG14076A (cs)
ES (1) ES477547A1 (cs)
FI (1) FI65777C (cs)
FR (1) FR2416891A1 (cs)
GB (1) GB2014140B (cs)
GR (1) GR72776B (cs)
HU (1) HU179970B (cs)
IE (1) IE47827B1 (cs)
IL (1) IL56581A (cs)
LU (2) LU80886A1 (cs)
MX (2) MX5995E (cs)
MY (1) MY8500597A (cs)
NL (1) NL930106I2 (cs)
NZ (1) NZ189561A (cs)
PH (1) PH14903A (cs)
PL (3) PL126313B1 (cs)
PT (1) PT69172B (cs)
RO (3) RO81857A (cs)
SU (1) SU912045A3 (cs)
UA (1) UA6082A1 (cs)
YU (1) YU28279A (cs)
ZA (1) ZA79453B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246265A (en) * 1979-10-01 1981-01-20 Eli Lilly And Company 6-n-Propyl-8α-methoxymethyl or methylmercaptomethylergolines and related compounds
US4382940A (en) * 1979-12-06 1983-05-10 Farmitalia Carlo Erba S.P.A. Ercoline derivatives and therapeutic compositions having CNS affecting activity
CH649998A5 (de) * 1982-08-09 1985-06-28 Sandoz Ag Ergolinderivate, ein verfahren zu ihrer herstellung und heilmittel, enthaltend diese ergolinderivate als wirkstoff.
US4563461A (en) * 1983-03-10 1986-01-07 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4551529A (en) * 1983-10-06 1985-11-05 Warner-Lambert Company Guanine-N7 -oxide
DE3340025C2 (de) * 1983-11-03 1986-01-09 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 2-Brom-8-ergolinyl-Verbindungen
US4675322A (en) * 1984-12-10 1987-06-23 Eli Lilly And Company 1-Substituted-6-n-propyl-8β-methylthio-methylergolines
GB2173189B (en) * 1985-02-21 1988-04-27 Maruko Pharmaceutical Co Ergoline derivatives and salts thereof and pharmaceutical compositions thereof
US4683313A (en) * 1985-06-24 1987-07-28 Eli Lilly And Company 2-alkyl(or phenyl)thio-6-N alkyl ergolines and 4-dialkylaminotetrahydrobenz[c,d]indoles
US4782152A (en) * 1985-08-16 1988-11-01 Eli Lilly And Company Decyanation of pergolide intermediate
US4772709A (en) * 1985-10-01 1988-09-20 Eli Lilly And Company Process of making ketoalkanol esters of dihydrolysergic acid
HU196394B (en) * 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4798834A (en) * 1987-08-31 1989-01-17 Eli Lilly And Company Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
DE3868866D1 (de) * 1987-11-20 1992-04-09 Erba Carlo Spa Ergolinderivate mit antiparkinsonwirkung.
DE3913756A1 (de) * 1989-04-21 1990-10-25 Schering Ag 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
DE3938701A1 (de) * 1989-11-20 1991-05-23 Schering Ag Neue agroclavin- und elymoclavin-derivate, verfahren zu deren herstellung und deren verwendung in arzneimitteln
US5063234A (en) * 1990-05-25 1991-11-05 Eli Lilly And Company Method of inhibiting demineralization of bone
DK0483077T3 (da) * 1990-09-28 1996-04-15 I F L O S A S Di Giorgio E Ald Fremgangsmåde til syntese af et kontraceptivt og menstruationscyklus-kontrollerende lægemiddel med onkostatiske, antikinetosiske, præventive og terapeutiske egenskaber til behandling af brysttumorer og melanomer
US5416090A (en) * 1991-01-31 1995-05-16 Eli Lilly And Company Method of treating inflammation
US5463060A (en) 1992-05-21 1995-10-31 Eli Lilly And Company One-pot process
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
IT1307934B1 (it) 1999-01-27 2001-11-29 Poli Ind Chimica Spa Processo per la preparazione di derivati alchimercaptometilergolinici.
AU2635599A (en) * 1999-03-17 2000-10-04 Eugen Eigenmann Use of prolactin inhibitors for the treatment of fertility problems in animal species
US6548484B1 (en) 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
US6388079B1 (en) 2000-08-29 2002-05-14 Scinopharm Singapore Pte Ltd. Process for preparing pergolide
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
PT2062914E (pt) * 2001-06-08 2014-07-18 Ipsen Pharma Sas Análogos quiméricos de somatostatina-dopamina
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
ATE414704T1 (de) * 2002-03-15 2008-12-15 Antibioticos Spa Verfahren zur synthese von pergolid
GB0409785D0 (en) 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
US7939665B2 (en) * 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2113504A1 (en) * 2008-04-29 2009-11-04 LEK Pharmaceuticals D.D. Preparation of N-6 demethylated, 9,10-dihydrolysergic acid alkyl esters
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
JP2016503402A (ja) 2012-11-01 2016-02-04 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体及びそのダイマー
WO2014092006A1 (ja) 2012-12-10 2014-06-19 キッセイ薬品工業株式会社 新規なオクタヒドロピリドキナゾリン誘導体、それを含有する医薬組成物およびそれらの用途
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920664A (en) * 1972-07-21 1975-11-18 Lilly Co Eli D-2-halo-6-alkyl-8-substituted ergolines and related compounds
AR206772A1 (es) * 1972-07-21 1976-08-23 Lilly Co Eli Procedimiento para preparar una nueva d-2-halo-6-metil-8-ciano(carboxamido)metil ergolina
IE41533B1 (en) * 1974-03-14 1980-01-30 Sandoz Ltd Thiomethyl ergolene derivatives
US3901894A (en) * 1974-06-06 1975-08-26 Lilly Co Eli 8-thiomethylergolines
US3985752A (en) * 1974-12-06 1976-10-12 Eli Lilly And Company 6-Methyl-8-(substituted) methylergolines
US3959288A (en) * 1974-12-13 1976-05-25 Eli Lilly And Company 8-Oxymethylergolines and process therefor
US4054660A (en) * 1975-04-14 1977-10-18 Eli Lilly And Company Method of inhibiting prolactin
JPS5283894A (en) * 1976-01-01 1977-07-13 Lilly Co Eli 88thiomethyl ergoline

Also Published As

Publication number Publication date
HU179970B (en) 1983-01-28
FI790351A (fi) 1979-08-09
EG14076A (en) 1983-12-31
US4166182A (en) 1979-08-28
RO81857A (ro) 1983-06-01
DE19375112I2 (de) 2003-06-12
IE47827B1 (en) 1984-06-27
DE2963320D1 (en) 1982-09-02
UA6082A1 (uk) 1994-12-29
IE790232L (en) 1979-08-08
GR72776B (cs) 1983-12-05
PL126313B1 (en) 1983-07-30
PT69172B (pt) 1992-05-29
SU912045A3 (ru) 1982-03-07
NL930106I2 (nl) 1997-02-03
BG30474A3 (en) 1981-06-15
AT371817B (de) 1983-08-10
JPS54115400A (en) 1979-09-07
RO81857B (ro) 1983-05-30
ES477547A1 (es) 1980-04-16
AR228341A1 (es) 1983-02-28
DD141928A5 (de) 1980-05-28
MY8500597A (en) 1985-12-31
LU88294I2 (fr) 1994-05-04
CS203951B2 (en) 1981-03-31
FR2416891A1 (fr) 1979-09-07
FR2416891B1 (cs) 1981-10-16
RO81856A (ro) 1983-06-01
BE873883A (fr) 1979-08-02
GB2014140B (en) 1982-08-04
CH639088A5 (fr) 1983-10-31
EP0003667A1 (en) 1979-08-22
DK147362B (da) 1984-07-02
AU523172B2 (en) 1982-07-15
DK51379A (da) 1979-09-18
NZ189561A (en) 1981-12-15
MX9203107A (es) 1992-07-31
IL56581A (en) 1982-05-31
PL124704B1 (en) 1983-02-28
AU4391779A (en) 1979-08-16
FI65777B (fi) 1984-03-30
LU80886A1 (fr) 1979-06-07
RO76889A (ro) 1981-08-30
ATA91479A (de) 1982-12-15
PT69172A (en) 1979-03-01
EP0003667B1 (en) 1982-07-14
JPS6363544B2 (cs) 1988-12-07
RO81856B (ro) 1983-05-30
PL213283A1 (cs) 1980-02-25
NL930106I1 (nl) 1993-10-18
CA1114368A (en) 1981-12-15
IL56581A0 (en) 1979-05-31
MX5995E (es) 1984-09-18
GB2014140A (en) 1979-08-22
ZA79453B (en) 1980-09-24
FI65777C (fi) 1984-07-10
PH14903A (en) 1982-01-29
PL120849B1 (en) 1982-03-31
YU28279A (en) 1983-02-28

Similar Documents

Publication Publication Date Title
DK147362C (da) Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf
DK162714C (da) Analogifremgangsmaade til fremstilling af glycinamidderivater eller syreadditionssalte deraf
DK149594C (da) Analogifremgangsmaade til fremstilling af dipeptidderivater eller syreadditionssalte heraf
DK145119C (da) Analogifremgangsmaade til fremstilling af phenolethere eller syreadditionssalte deraf
DK164545C (da) Analogifremgangsmaade til fremstilling af sulfonylamino- eller sulfonylaminoalkylphenoxyalkylcarbonsyrederivater eller fysiologisk uskadelige salte deraf
DK150512C (da) Analogifremgangsmaade til fremstilling af 3-quino-lincarboxylsyrederivater eller syreadditionssalte deraf
DK143275C (da) Analogifremgangsmaade til fremstilling af 1-(3-dimethylaminopropyl)-phthalanderivater eller syreadditionssalte deraf
DK178379A (da) Fremgangsmaade til fremstilling af n-substituerede moranolinderivater eller syreadditionssalte deraf
DK148477C (da) Analogifremgangsmaade til fremstilling af tetrahydropyridinylindolderivater eller additionssalte deraf
DK145260C (da) Analogifremgangsmaade til fremstilling af 4-acylamino-phenyl-ethanolaminer eller syreadditionssalte heraf
DK149609C (da) Analogifremgangsmaade til fremstilling af hydroxyamino-alkan- eller -alkenphosphonsyrederivater eller estere eller salte deraf
DK149630C (da) Analogifremgangsmaade til fremstilling af tripeptidamider eller -estere eller fysiologisk acceptable syreadditionssalte deraf
DK157862C (da) Analogifremgangsmaade til fremstilling af imidazolylphenylamidiner eller farmaceutisk acceptable syreadditionssalte deraf
DK147940C (da) Analogifremgangsmaade til fremstilling af 4-substituerede thiazol-2-oxamsyrederivater eller salte eller estre deraf
DK149231C (da) Analogifremgangsmaade til fremstilling af enkephalin-analoge tetrapeptidamider eller syreadditionssalte deraf
DK147942C (da) Analogifremgangsmaade til fremstilling af kanamycin a- eller kanamycin b-derivater eller syreadditionssalte deraf
DK146281C (da) Analogifremgangsmaade til fremstilling af 2-brom-6-fluor-n-2-imidazolidinyliden-benzamin eller syreadditionssalte heraf
DK159079A (da) Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf
DK146066C (da) Analogifremgangsmaade til fremstilling af substituerede 2-phenylimino- imidazolidiner eller syreadditionssalte deraf
DK142544C (da) Analogifremgangsmaade til fremstilling af 2-(n-propargyl-n-phenylamino)-imidazolin-(2)-derivater eller fysiologisk acceptable syreadditionssalte heraf
DK149077C (da) Analogifremgangsmaade til fremstilling af encephalin-analoge pentapeptidamidderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK149841C (da) Analogifremgangsmaade til fremstilling af alfa-fluor-methyl-alfa-aminoalkansyrer eller farmaceutisk acceptable syreadditionssalte deraf
DK165005C (da) Analogifremgangsmaade til fremstilling af 4,5-dihydro-4-oxofuran-2-carboxylsyrederivater eller terapeutisk acceptable salte deraf
DK152427C (da) Analogifremgangsmaade til fremstilling af 4-thiomethylpyridinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK144793C (da) Analogifremgangsmaade til fremstilling af dihydro- eller tetrahydroiminothiaziner eller farmaceutisk acceptable syreadditionssalte deraf

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1994 00009, 940803

CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1994 00009, 940803

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1994 00009, 940803, EXPIRES: 20040207

PUP Patent expired